Machine Learning Model Predicts Risk of Upgrade to Breast CA

Share this content:
Machine Learning Model Predicts Risk of Upgrade to Breast CA
Machine Learning Model Predicts Risk of Upgrade to Breast CA

TUESDAY, Oct. 17, 2017 (HealthDay News) -- A machine learning model can predict the risk of upgrade of high-risk breast lesions (HRLs) to cancer, according to a study published online Oct. 17 in Radiology.

Manisha Bahl, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues identified consecutive patients with biopsy-proven HRLs who underwent surgery or at least two years of imaging follow-up. To identify HRLs at low risk for upgrade to cancer, a random forest machine learning model was developed. The model included traditional features such as age and HRL histologic results and also text features from the biopsy pathologic report.

A total of 1,006 HRLs were identified, and they had a cancer upgrade rate of 11.4 percent. The researchers developed the model with 671 HRLs and tested it with an independent set of 335 HRLs. Age and HRL histologic results were among the most important traditional features; "severely atypical" was an important text feature from the pathologic reports. If those categorized with the model to be at low risk for upgrade underwent surveillance and the remainder were excised instead of surgical excision of all HRLs, 97.4 percent of malignancies would have been diagnosed at surgery and 30.6 percent of surgeries of benign lesions could have been avoided.

"Use of this model could decrease unnecessary surgery by nearly one-third and could help guide clinical decision making with regard to surveillance versus surgical excision of HRLs," the authors write.

Two authors disclosed having a patent in process with Massachusetts General Hospital and the Massachusetts Institute of Technology, and one author disclosed ties to GE Healthcare.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »